Compare Options
Deciding whether to pursue a stem cell transplant is deeply personal and often complex. You may feel ready to weigh the risks and benefits yourself, or you may prefer to lean on your medical team’s recommendation. This information is here to help you understand the considerations involved, so you can have a thoughtful, informed conversation with your doctor about what feels right for you.
The table below compares two possible approaches for people with RUNX1-FPD.
| Getting a stem cell transplant | Not getting a stem cell transplant | |
|---|---|---|
| What is the main goal of this option? | To replace the bone marrow cells that carry the RUNX1 mutation and potentially prevent the development of leukemia or related blood cancers. | To carefully monitor your health and begin treatment only if signs of disease progression appear. |
| What are the potential benefits? | May reduce or eliminate the risk of developing certain blood cancers associated with RUNX1-FPD. May also correct some blood or platelet abnormalities related to the disorder. | Avoids the immediate risks and side effects of transplant. Allows you to maintain your current health status while monitoring for changes over time. |
| What are the possible risks or downsides? | Transplant is a major medical procedure and may lead to serious complications, including infections, graft-versus-host disease (GVHD), graft failure, or other long-term health effects. Recovery can take months to years. | The underlying genetic condition remains, and there is still a risk that leukemia or another blood disorder may develop later. Some people may experience uncertainty or anxiety related to ongoing monitoring. |
| What does recovery or follow-up look like? | After transplant, patients require close medical monitoring. This includes frequent visits, medications to prevent complications, and long-term follow-up to manage possible side effects. | Monitoring usually continues throughout life. Your care team may recommend regular blood counts and occasional bone marrow testing to watch for early signs of disease progression. |
| When might this option be considered? | Some individuals consider transplant if they have a suitable donor, signs of disease progression, or other clinical factors that suggest transplant may be beneficial. | This approach may be chosen when a person prefers to avoid transplant risks unless it becomes clearly necessary or when the medical team recommends continued monitoring. |
| How certain are doctors about the outcome? | Transplant may prevent malignancy, but it also carries serious risks and long-term effects. Doctors cannot guarantee the outcome. | Monitoring avoids transplant risks now, but it cannot prevent malignancy if it develops later. |
| What factors might influence this decision? | May be considered if there are signs of disease progression, high-risk mutations, or a suitable donor. | May be chosen if disease risk appears stable or if the person prefers to avoid transplant risks unless clearly necessary. |
| What role do personal preferences play? | Some people prefer to address the risk early, even if the procedure has significant risks. | Others prefer to delay treatment and avoid major procedures unless disease develops. |
-
Clonal evolution and genetic progression to malignancy
The comparison of treatment options presented in this section is based on published research on RUNX1 familial platelet disorder (RUNX1-FPD), the risk of progression to myeloid malignancies, and outcomes associated with hematopoietic stem cell transplantation.
Liu J, Tran D, Xue L, et al. Germline genetic variation shapes clonal hematopoiesis and progression to malignancy. Nature Genetics. 2025.
Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine. 2014;371:2488–2498.
Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequencing. New England Journal of Medicine. 2014;371:2477–2487.
(Refs 7, 28, 29 from the manuscript)
Outcomes of hematopoietic stem cell transplantation
Evidence on survival outcomes, transplant approaches, and long-term effectiveness of allogeneic hematopoietic stem cell transplantation.
Penack O, Peczynski C, Mohty M, et al. Changes in transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Blood Advances. 2020;4(24):6283–6290.
Mateos MK, O’Brien TA, Oswald C, et al. Transplant-related mortality following allogeneic hematopoietic stem cell transplantation for leukemia. Pediatric Blood & Cancer. 2013;60(9):1520–1527.
Spellman SR, Xu K, Oloyede T, et al. Trends and outcomes in allogeneic hematopoietic cell transplantation.
(Refs 49–54 from the manuscript)
Transplant complications and long-term risks
Studies describing major risks associated with transplantation, including graft-versus-host disease (GVHD), infection, and graft failure.
EBMT Chronic Malignancy Working Party. Allogeneic stem cell transplantation outcomes in lower-risk myelodysplastic syndromes. Bone Marrow Transplantation. 2017;52(2):209–215.
Kanda Y, et al. Infectious complications following allogeneic hematopoietic stem cell transplantation. Journal of Infection and Chemotherapy. 2016;22(8):505–514.
Mata JR, Zahurak M, Rosen N, DeZern AE, Jones RJ, Ambinder AJ. Graft failure after non-myeloablative allogeneic transplantation: incidence and outcomes. Transplantation and Cellular Therapy. 2024;30(6):588–596.
(Refs 61, 72, 79 from the manuscript)